Management of Apixaban-Associated Bleeding in Trauma

Introduction to Andexanet Alfa

The American College of Cardiology recommends administering andexanet alfa IV immediately as the specific FDA-approved reversal agent for apixaban-associated life-threatening bleeding, using the high-dose regimen, in patients with catastrophic injuries and hemodynamic instability 1, 2
Andexanet alfa is the only FDA-approved specific reversal agent for apixaban and should be administered without delay in life-threatening bleeding scenarios, such as polytrauma with intracranial hemorrhage, pelvic fracture, and hemorrhagic shock, as recommended by the International Society on Thrombosis and Haemostasis 1, 2

The 2024 ISTH guidelines and 2020 ACC Expert Consensus explicitly recommend andexanet alfa as first-line therapy for patients on factor Xa inhibitors presenting with major bleeding, particularly intracranial hemorrhage, with a high strength of evidence 1, 2
Andexanet alfa reduces anti-factor Xa activity by 93-94% within 2-5 minutes of administration, with effects sustained throughout the infusion period, as reported in the Journal of Thrombosis and Haemostasis 1

The high-dose andexanet alfa regimen is indicated when the last apixaban dose was >5 mg taken <8 hours prior or timing is unknown, as recommended by the American College of Cardiology 2
The high-dose regimen consists of 800 mg IV bolus at 30 mg/min, followed by 960 mg continuous infusion at 8 mg/min for up to 120 minutes, as specified in the Journal of the American College of Cardiology 2

In the ANNEXA-4 trial, 80% of patients achieved excellent or good hemostatic efficacy at 12 hours after andexanet administration for major bleeding events, with a moderate strength of evidence 1
For intracranial hemorrhage specifically, 79% of patients achieved hemostatic success defined as <35% hematoma expansion at 12 hours, as reported in the journal Stroke 4

The reversal effect of andexanet alfa is transient, with anti-factor Xa activity returning toward baseline approximately 2 hours after completing the infusion, emphasizing the need for definitive bleeding control measures, as recommended by the International Society on Thrombosis and Haemostasis 1
Thrombotic events occur in approximately 10-18% of patients within 30 days, emphasizing the need for careful thromboprophylaxis consideration once hemostasis is achieved, with a low strength of evidence 1

If andexanet alfa is not available, four-factor prothrombin complex concentrate (4F-PCC) at 50 units/kg IV or activated PCC may be administered, though these are less effective and lack FDA approval for apixaban reversal, as recommended by the World Journal of Emergency Surgery 5, 2

Simultaneous neurosurgical consultation for potential craniotomy and orthopedic trauma consultation for pelvic stabilization and femur fracture management are recommended, as these injuries are major sources of ongoing hemorrhage, as specified in the World Journal of Emergency Surgery and Praxis Medical Insights 3, 5
Massive transfusion protocol activation with balanced blood product resuscitation while andexanet is being administered is also recommended, as reported in the World Journal of Emergency Surgery 5